CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma

Exclusion Criteria

• •1. Central nervous system (CNS) only involvement by malignancy or primary CNS lymphoma;
• •2. History of another primary malignancy that has not been in remission for at least 2 years;
• •3. Subjects has HBV, HCV, HIV or syphilis infection at the time of screening;
• •4. Deep venous thrombosis (DVT)/Pulmonary embolism (PE), or DVT/PE requires anti-coagulation within 3 months prior to signing the ICF;
• •5. Subjects with uncontrolled systemic fungal, bacterial, viral or other infection;
• •6. Presence of acute or chronic graft-versus-host disease (GVHD);
• •7. History of any serious cardiovascular disease or presence of clinically relevant CNS pathology;
• •8. Pregnant or nursing women;
• •9. Subjects using of any chemotherapy, corticisteriod, experiment agents, GVHD therapies, radiation, allo-HSCT or any other therapies for lymphoma must go through a specific wash-out period before leukapheresis;
• •10. Uncontrolled conditions or unwillingness or inability to follow the procedures required in the protocol;
• •11. Received CAR T-cell or other genetically-modified T-cell therapy previously.